logo-loader
viewGenprex, Inc.

Genprex boosts management team with two key hires

Eric Chapdelaine joins the gene-therapy company as a senior director of pharmaceutical sciences and manufacturing and Kalyn Dabbs as a senior manager of communications and marketing

cancer in headline
Genprex is making great strides toward developing its lung cancer-fighting, gene-therapy treatment Oncoprex

Genprex Inc (NASDAQ:GNPX), the cancer-focused gene therapy company, is adding to its management, with the hiring of Eric Chapdelaine as a senior director of pharmaceutical sciences and manufacturing, and Kalyn Dabbs as a senior manager of communications and marketing.

In his new role, Chapdelaine will oversee Genprex’s manufacturing as well as its technical operations and supply chain management.

He joins Genprex from Cognate BioServices where he served as the director of quality control and analytical development and oversaw a staff of more than 40 working on cell and gene therapy in laboratories.

READ: Genprex, Aldevron report progress in clinical trials for lung-cancer therapy Oncoprex

Dabbs, meanwhile, will take responsibility for communications as well as marketing plans and the company’s digital strategy. Before signing on at Genprex, Dabbs spent six years working in various communications and marketing roles in the healthcare and wellness industries.

Rodney Varner, Genprex’s CEO and chairman, spoke with enthusiasm about both hires.

“Eric’s experience at both biotech companies and contract development and manufacturing organizations will be invaluable in managing and coordinating manufacturing partners and scale-up activities as we expand our research and development efforts and clinical trials of our lead product candidate, Oncoprex™, at the University of Texas MD Anderson Cancer Center and potentially other clinical sites,” Varner said.

READ: Genprex appoints new vice president of clinical operations

“Kalyn's role with our company will be essential as we execute our shareholder outreach and communications strategy in the coming year,” he added.

Based in Austin, Texas, Genprex is making great strides toward developing its lung cancer-fighting, gene-therapy treatment Oncoprex.

Genprex shares nudged up almost 1% to $1.46 in morning trade on Wednesday.

Contact Ellen Kelleher at [email protected]

Quick facts: Genprex, Inc.

Price: 0.34 USD

NASDAQ:GNPX
Market: NASDAQ
Market Cap: $5.39 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Genprex's active drug ingredient validated by independent...

Genprex (NASDAQ:GNPX) CEO Rodney Varner tells Proactive that the active ingredient in the biotech firm's immunogene therapy Oncoprex has been shown to prevent tumor growth in triple-negative breast cancer patients by an independent researcher. Varner notes the study was published in the...

on 09/20/2019

2 min read